GH Research PLC is expected to report a third-quarter net loss of $0.31 per share on $0.00 in revenue, with shares currently trading around $18.14 relative to a bullish $45.80 average analyst price target. Investors are predominantly focused on the clinical and regulatory timeline for lead candidate GH001, a proprietary mebufotenin formulation for treatment-resistant depression.
The update is expected to provide critical details on the initiation of the global Phase 3 pivotal program and the scheduled End-of-Phase 2 FDA meeting in early 2027. Analysts are also closely monitoring the company's capital allocation and cash runway, which stood at $350.6 million as of September 30, to ensure the firm can reach key clinical milestones without further dilution.